For the quarter ending 2026-03-31, TECH made $311,415K in revenue. $46,535K in net income. Net profit margin of 14.94%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net sales | 311,415 | 295,877 | 286,555 | 316,965 |
| Cost of sales | 103,127 | 104,600 | 98,443 | 118,152 |
| Gross margin | 208,288 | 191,277 | 188,112 | 198,813 |
| Selling, general and administrative | 109,338 | 113,691 | 116,213 | 196,640 |
| Research and development | 23,455 | 23,125 | 24,241 | 26,032 |
| Total operating expenses | 132,793 | 136,816 | 140,454 | 222,672 |
| Operating income | 75,495 | 54,461 | 47,658 | -23,859 |
| Interest expense | - | - | - | 2,178 |
| Interest income | - | - | - | 2,971* |
| Other non-operating income (expense), net | - | - | - | 208* |
| Other income (expense) | -4,270 | -3,677 | 333 | 1,001 |
| Earnings before income taxes | 71,225 | 50,784 | 47,991 | -22,858 |
| Income taxes | 20,178 | 12,775 | 9,806 | -5,180 |
| Net earnings | - | - | - | -17,678 |
| Net earnings | 51,047 | 38,009 | 38,185 | -17,678 |
| Foreign currency translation income (loss) | -4,352 | 2,762 | -2,850 | 22,953 |
| Unrealized gains (losses) on derivative instruments | -160 | -711 | -1,665 | -781 |
| Other comprehensive income (loss) | -4,512 | 2,051 | -4,515 | 22,172 |
| Other comprehensive income (loss) attributable to bio-techne | - | - | - | 22,172 |
| Comprehensive income | 46,535 | 40,060 | 33,670 | 4,494 |
| Basic EPS | 0.33 | 0.24 | 0.25 | 0.029 |
| Diluted EPS | 0.32 | 0.24 | 0.24 | 0.028 |
| Basic Average Shares | 156,327,000 | 155,839,000 | 155,464,000 | 155,750,000 |
| Diluted Average Shares | 157,403,000 | 156,999,000 | 156,362,000 | 158,183,000 |
BIO-TECHNE Corp (TECH)
BIO-TECHNE Corp (TECH)